SCHEMBL3979529

SCHEMBL3979529

CCOC(=O)c1occc1-c1cccc(OCc2cccc(N)c2)c1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.44
JAK3 P52333 1/20 0.44
ACHE P22303 1/20 0.43
PPARG P37231 1/20 0.42
MAOB P27338 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MRGPRX4 Q96LA9 4/20 0.41
FFAR1 O14842 3/20 0.40
PPARD Q03181 2/20 0.40
CFD P00746 1/20 0.39
CYP2D6 P10635 1/20 0.39
TP53 P04637 1/20 0.39
CYP3A4 P08684 1/20 0.39
ESR1 P03372 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3976847 0.86 SMN1; SMN2 (0.53) SMN1; SMN2KDM4EALDH1A1MAPTL3MBTL1
SCHEMBL3980486 0.84 MAOB (0.53) MAOBALDH1A1MAPTFFAR1CYP2D6
SCHEMBL3981898 0.84 PTGER4 (0.42) JAK2JAK3PPARGSMN1; SMN2KDM4E
SCHEMBL3974986 0.82 PTGER4 (0.44) JAK2JAK3ACHEPPARGMAOB
SCHEMBL3975517 0.81 ALDH1A1 (0.42) JAK2JAK3PPARGMAOBKDM4E
SCHEMBL27605303 0.81 JAK2 (0.39) JAK2JAK3PPARGMAOBMAPT
SCHEMBL3977084 0.78 ALDH1A1 (0.52) SMN1; SMN2KDM4EALDH1A1MAPTL3MBTL1
SCHEMBL3977097 0.78 FNTA (0.46) JAK2JAK3KDM4EALDH1A1MAPT
SCHEMBL3975215 0.77 PPARG (0.53) PPARGMAOBALDH1A1MAPTL3MBTL1
SCHEMBL3979355 0.77 MAPT (0.45) SMN1; SMN2KDM4EALDH1A1MAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514452-B2 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD (JP) 2009-04-07 US disclosed
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-04 US disclosed
EP-1489077-A1 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same GLP1R, GCGR, GPR119 JAK2 2506/4885JAK3 4229/4885ACHE 1893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.